• Title/Summary/Keyword: Cholesterol-induced cardiac hypertrophy

Search Result 4, Processing Time 0.016 seconds

Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells

  • Lee, Hyunjung;Park, Jinyoung;Kim, Eunice EunKyeong;Yoo, Young Sook;Song, Eun Joo
    • BMB Reports
    • /
    • v.49 no.5
    • /
    • pp.270-275
    • /
    • 2016
  • The Ubiquitin proteasome system (UPS) plays roles in protein degradation, cell cycle control, and growth and inflammatory cell signaling. Dysfunction of UPS in cardiac diseases has been seen in many studies. Cholesterol acts as an inducer of cardiac hypertrophy. In this study, the effect of proteasome inhibitors on the cholesterol-induced hypertrophic growth in H9c2 cells is examined in order to observe whether UPS is involved in cardiac hypertrophy. The treatment of proteasome inhibitors MG132 and Bortezomib markedly reduced cellular surface area and mRNA expression of β-MHC in cholesterol-induced cardiac hypertrophy. In addition, activated AKT and ERK were significantly attenuated by MG132 and Bortezomib in cholesterol-induced cardiac hypertrophy. We demonstrated that cholesterol-induced cardiac hypertrophy was suppressed by proteasome inhibitors. Thus, regulatory mechanism of cholesterol-induced cardiac hypertrophy by proteasome inhibitors may provide a new therapeutic strategy to prevent the progression of heart failure.

Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats

  • Lee, Eunjo;Song, Min-ji;Lee, Hae-Ahm;Kang, Seol-Hee;Kim, Mina;Yang, Eun Kyoung;Lee, Do Young;Ro, Seonggu;Cho, Joong Myung;Kim, Inkyeom
    • The Korean Journal of Physiology and Pharmacology
    • /
    • v.20 no.5
    • /
    • pp.477-485
    • /
    • 2016
  • CG200745 is a novel inhibitor of histone deacetylases (HDACs), initially developed for treatment of various hematological and solid cancers. Because it is water-soluble, it can be administered orally. We hypothesized that the HDAC inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in deoxycorticosterone acetate (DOCA)-induced hypertensive rats. For establishment of hypertension, 40 mg/kg of DOCA was subcutaneously injected four times weekly into Sprague-Dawley rats. All the rats used in this study including those in the sham group had been unilaterally nephrectomized and allowed free access to drinking water containing 1% NaCl. Systolic blood pressure was measured by the tail-cuff method. Blood chemistry including sodium, potassium, glucose, triglyceride, and cholesterol levels was analyzed. Sections of the heart were visualized after trichrome and hematoxylin and eosin stain. The expression of hypertrophic genes such as atrial natriuretic peptide A (Nppa) and atrial natriuretic peptide B (Nppb) in addition to fibrotic genes such as Collagen-1, Collagen-3, connective tissue growth factor (Ctgf), and Fibronectin were measured by quantitative real-time PCR (qRT-PCR). Injection of DOCA increased systolic blood pressure, heart weight, and cardiac fibrosis, which was attenuated by CG200745. Neither DOCA nor CG200745 affected body weight, vascular contraction and relaxation responses, and blood chemistry. Injection of DOCA increased expression of both hypertrophic and fibrotic genes, which was abrogated by CG200745. These results indicate that CG200745 attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.

The Effect of Laser Acupuncture of Five-Transport-Points of the Heart Meridian in L-NAME-Induced Hypertensive Rats (수소음심경 오수혈 혈위별 레이저 침자가 고혈압 흰쥐의 혈압에 미치는 영향)

  • Shin, Wook;Lee, Yumi;Kim, Wangin;Choi, Donghee;Kim, Mirae;Youn, Daehwan;Na, Changsu
    • Korean Journal of Acupuncture
    • /
    • v.34 no.1
    • /
    • pp.56-69
    • /
    • 2017
  • Objectives : The purpose of this study is to compare the effects of laser acupuncture to the 532 nm on the five transport points with the heart meridian for treatment to hypertensive disease in rats with L-NAME induced hypertensive. Methods : Hypertensive was induced by L-NAME for 3 weeks. The laser acupuncture therapy on the five transport points of heart meridian(Laser Well Point-HT9, Laser Brook Point-HT8. Laser Stream Point-HT7, Laser River Point-HT4 and Laser Sea Point-HT3) was treated twice a week for 5 times. The hypertensive was measured using a cardiac hypertrophy, atherogenic index, TG/HDL-cholesterol ratio, TCHO, HDLC, TG, AST, ALT, antioxidative effectiveness and glutathione peroxidase quality of hypertensive rats induced by L-NAME. Results : Blood pressure were decreased significantly after the laser acupuncture of Well, Brook and Sea Point groups. Cardiac hypertrophy were decreased at the laser acupuncture of Brook and Stream Point groups. Athrogenic index was decreased at the laser acupuncture of Well, Stream, River and Sea Point groups. TG/HDL-cholesterol ratio was decreased at the laser acupuncture of all groups. Total cholesterol was decreased significantly at the laser acupuncture of Well Point group. High density lipoprotein cholesterol and total cholesterol were decreased significantly at the laser acupuncture of Well, Stream and River Point groups. Triglyceride was decreased significantly at the laser acupuncture of Stream Point group. Cu/Zn-Superoxide Dismutase (Cu/Zn-SOD) and glutathione peroxidase(GPX) were increased significantly at the laser acupuncture of Well Point group. Conclusions : The laser acupuncture treatment in five transport points of the Heart Meridian was effective for lowering blood pressure, cardiac hypertrophy, Atherogenic index and HTR, and for enhancing antioxidant activity.

PATHOLOGICAL STUDIES ON THE CHRONIC TOXICITY OF METHAMPHETAMINE ADMINISTRATION

  • Rim, Byung-Moo;Cho, Gye-Myung;Chang, Jae-Hong
    • Toxicological Research
    • /
    • v.9 no.2
    • /
    • pp.233-240
    • /
    • 1993
  • Toxic effects of chronic adminstration of methamphetamine (MA) to SD rats were studied in respect to histopathological changes induced in each organ. In experimental groups liver weight decreased and brain weights increased markedly compared with controls in the 12th month after subcutaneous injection of 0.5 mg and 5mg/kg/BW MA. Serum alkaline phosphotase levels increased, but marked decrease of cholesterol, triglyceride, and BUN levels were checked depending on both the dose of MA and duration of treatment.

  • PDF